ResoTher Pharma A/S: Financial statements 2025
CVR: 37852406
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
ResoTher Pharma A/S (CVR 37852406) has filed annual accounts for 2025. Equity in the 2025 report amounted to DKK 12,132,000. The solvency ratio was 74%. The company had 3 employees in the financial year.
- Equity
- DKK 12,132,000
- Total Assets
- DKK 16,387,000
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | - | - | 12.1M | 3 |
| 2024 | - | - | -10.1M | 12.1M | - |
| 2023 | - | - | - | 20.8M | 2 |
| 2022 | - | - | -27.2M | 12.2M | 3 |
| 2021 | - | - | -11.7M | 38.6M | 3 |
Official annual report
How creditworthy is ResoTher Pharma A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of December 15, 2025, Thomas Engelbrecht Nordkild Jonassen has joined the board of directors of ResoTher Pharma A/S.
As of December 15, 2025, Rebecca Anne Morison has joined the board of directors of ResoTher Pharma A/S.
As of December 14, 2025, Thomas Engelbrecht Nordkild Jonassen has left the board of directors of ResoTher Pharma A/S.
As of December 14, 2025, Rebecca Anne Morison has left the board of directors of ResoTher Pharma A/S.
As of September 23, 2025, Rebecca Anne Morison has joined the board of directors of ResoTher Pharma A/S.
ResoTher Pharma A/S has published its annual report for 2024. The net result was DKK -10,071,000.
As of June 23, 2025, Thomas Engelbrecht Nordkild Jonassen has joined the board of directors of ResoTher Pharma A/S.
As of June 23, 2025, Kirsten Aarup Drejer has left the board of directors of ResoTher Pharma A/S.
As of June 23, 2025, Thomas Feldthus has left the board of directors of ResoTher Pharma A/S.
About ResoTher Pharma A/S
ResoTher Pharma A/S is a Danish company of the type Aktieselskab based in Holte, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ResoTher Pharma ApS. The management consists of Anders Kronborg. The board consists of Rebecca Anne Morison (chair), Henrik Stage, Jeppe Øvli Øvlesen and Michael Østerlund Madsen. The company is owned by Quantass ApS and TJ Biotech Holding ApS. The company has 4 employees (2026). Equity in the 2025 report amounted to DKK 12,132,000.